Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Why Are Alkermes Shares Trading Lower Today?
12:00pm, Wednesday, 27'th Oct 2021
Alkermes plc (NASDAQ: ALKS) posted Q3 sales of $294.1 million, up 11% Y/Y, missing the consensus of $301.36 million. Vivitrol sales increased 11% to $88.8 million, and Aristada sales increased 10%
Alkermes to Report Third Quarter 2021 Financial Results on Oct. 27, 2021
04:00pm, Wednesday, 20'th Oct 2021
DUBLIN, Oct. 20, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Top Ranked Momentum Stocks to Buy for October 13th
10:43am, Wednesday, 13'th Oct 2021
ALKS, BP, and E made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 13, 2021.
2 Supercharged Stocks Near 52-Week Highs Despite the Market Pullback
05:55am, Wednesday, 13'th Oct 2021
Are they stocks to buy near the highs?
Find 'Strong Buy' Stocks for October and Beyond with this Screener
02:55pm, Tuesday, 12'th Oct 2021
Given this backdrop, investors with long-term horizons should remain on the hunt for stocks because timing the market is difficult. Utilizing our Filtered Zacks Rank 5 Stock Screener is a great place
New Survey Provides Insights Into Drinking Behaviors During the Pandemic
07:00am, Wednesday, 22'nd Sep 2021
DUBLIN, Sept. 22, 2021 /PRNewswire/ -- A new online survey conducted during the COVID-19 pandemic by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), found tha
DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineere
BofA Downgrades Alkermes After Stock Rally: 'We Don't See A Favorable Catalyst Pathway'
11:01am, Thursday, 02'nd Sep 2021
Following the recent rally, Alkermes Plc's (NASDAQ:ALKS) shares have exceeded their fair value and the stock looks “expensive on a relative basis,” according to BofA Securities. The Alkermes Analy
What's Next For Alkermes Stock After A 16% Rise Last Month?
07:00am, Thursday, 02'nd Sep 2021
The stock price of Alkermes, a biopharmaceutical company focused on neuroscience and oncology, has seen a rise of around 16% over the last twenty-one trading days, and it is up a solid 91% over the la
Alkermes Receives FDA Fast Track Status For Mucosal Melanoma Immunotherapy
08:53am, Monday, 02'nd Aug 2021
The FDA has granted Fast Track designation to Alkermes plc's (NASDAQ: ALKS) nemvaleukin alfa (nemvaleukin) for mucosal melanoma. Nemvaleukin is an investigational engineered interleukin-2 (IL-2) v
Alkermes (ALKS) Beats on Q2 Earnings & Sales, Ups '21 View
12:55pm, Thursday, 29'th Jul 2021
Following a positive recovery from COVID-impacts, Alkermes (ALKS) beat both earnings and sales estimates in second-quarter 2021. The company also raised its guidance for 2021.
Alkermes Plc (ALKS) CEO Richard Pops on Q2 2021 Results - Earnings Call Transcript
02:50pm, Wednesday, 28'th Jul 2021
Alkermes Plc (ALKS) CEO Richard Pops on Q2 2021 Results - Earnings Call Transcript
Alkermes: Q2 Earnings Insights
07:27am, Wednesday, 28'th Jul 2021
Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 400.00% over the past year to $0.30, which beat the estimate of $0.12.
Alkermes plc Reports Second Quarter 2021 Financial Results
07:00am, Wednesday, 28'th Jul 2021
DUBLIN, July 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2021 and provided updated financial expectations for full-year 2021. "Alke
Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program
07:00am, Friday, 23'rd Jul 2021
DUBLIN, July 23, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the 2021 recipients of grants from the company's signature Alkermes Inspiration Grants® program. Grants were awarde
